Conference Coverage

Impaired kidney function no problem for dabigatran reversal


 

REPORTING FROM ACC 18


In patients with severe renal dysfunction given idarucizumab, “be alert for a recurrent bleed,” which could require a second dose of idarucizumab, Dr. Eikelboom suggested.

SOURCE: Eikelboom JW et al. ACC 18, Abstract 1231M-11.

Pages

Recommended Reading

VIDEO: PFO closure device 100% effective against future strokes
MDedge Cardiology
Warfarin dose capping avoided supratherapeutic INRs in hospitalized elderly
MDedge Cardiology
Protocol helped identify hospitalized children at risk for VTE
MDedge Cardiology
Few acutely ill hospitalized patients receive VTE prophylaxis
MDedge Cardiology
Two scoring systems helpful in diagnosing heparin-induced thrombocytopenia
MDedge Cardiology
The ‘holy grail’ of thrombosis prevention
MDedge Cardiology
Apixaban prevails in study of 163,000 DOAC users
MDedge Cardiology
Clopidogrel flunks platelet reactivity control test in TAVI
MDedge Cardiology
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Cardiology
VTE risk after bariatric surgery should be assessed
MDedge Cardiology